All PlansCoverageHigh impact
Denosumab Products: Denosumab (Xgeva®); Denosumab-kyqq (Aukelso™); Denosumab-nxxp (Bilprevda®); Denosumab-bnht (Bomyntra®); Denosumab-desu (Jubereq); Denosumab-bmwo (Osenvelt®); Denosumab-mobz (Oziltus®); Denosumab-bbdz (Wyost®); Denosumab-dssb (Xbryk™), Denosumab-qbde (Xtrenbo™)
BCBS Tennessee·TN · Oncology, Hematology, Palliative Care·Medical Policy
Effective date
Oct 31, 2026
We identified it
Aug 13, 2026
Summary
This is a new comprehensive medical policy covering 10 denosumab biosimilar products (Xgeva and 9 new biosimilars: Aukelso, Bilprevda, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, Xtrenbo). The policy establishes coverage criteria, authorization periods (12 months for most indications, 2 months for hypercalcemia), dosing limits, and continuation of therapy requirements across multiple oncology and bone-related indications. CRITICAL: Policy is approved but explicitly states 'Do Not Implement until 10/31/26'—no changes should be made until that date.
Action Required
By October 15, 2026 (16 days before effective date): Billing team must prepare implementation of denosumab biosimilar coverage policy. Tasks include: (1) Update billing system to recognize all 10 denosumab product names and their HCPCS codes (J0897 family codes for Xgeva/denosumab and corresponding J-codes for biosimilars); (2) Configure prior authorization rules requiring 12-month authorization for multiple myeloma, bone metastases, giant cell tumor of bone, and systemic mastocytosis; (3) Configure 2-month authorization for hypercalcemia of malignancy; (4) Implement dose limits in system (120mg on days 1, 8, 15 then every 4 weeks for most indications; 60mg every 6 months for systemic mastocytosis); (5) Train providers and billing staff on new biosimilar options and authorization requirements; (6) Update claim submission templates to capture diagnosis codes and medical necessity documentation; (7) Flag experimental/investigational indications (all others not listed) for automatic denial. Effective Date: October 31, 2026. Failure to implement by effective date will result in claim denials for unauthorized denosumab use and potential compliance violations with insurer coverage mandates.